Differential antiseizure medication sensitivity of the Affective Reactivity Index: A randomized controlled trial in new-onset pediatric focal epilepsy

David W. Loring, Kimford J. Meador, Shlomo Shinnar, William Davis Gaillard, James W. Wheless, Sudha K. Kessler, Joan A. Conry, Madison M. Berl, Thomas G. Burns, Tracy A. Glauser, Becky Kinkead, Avital Cnaan

Research output: Contribution to journalArticle

Abstract

Background: Irritability is a adverse effect of many antiseizure medications (ASMs), but there are no validated measures currently available to characterize this behavioral risk. We examined both child and parent/guardian versions of the Affective Reactivity Index (ARI), a validated measure developed for application in adolescent psychiatry, to determine its sensitivity to ASM-related irritability. We hypothesized irritability increases associated with levetiracetam (LEV) but not lamotrigine (LTG) or oxcarbazepine (OXC). Method: The ARI was administered to 71 child and parent/guardian pairs randomized to one of three common ASMs (LEV, LTG, OXC) used to treat new-onset focal (localization-related) epilepsy. Subjects were recruited as part of a prospective multicenter, randomized, open-label, parallel group design. The ARI was administered at baseline prior to treatment initiation and again at 3 months after ASM initiation. Results: There was a significant increase in ARI ratings for both child and parent/guardian ratings for LEV but not LTG or OXC when assessed 3 months after treatment initiation. When examined on the individual subject level using a criterion of at least a 3-point ARI increase, there was an increase associated with LEV for child ratings but not parent/guardian scores. Conclusion: Both child and parent/guardian versions of the ARI appear sensitive to medication-induced irritability associated with LEV on both the group and individual levels. The findings extend the applicability of ARI from characterizing the presence of clinical irritability as a psychiatric diagnostic feature to a more modifiable aspect of behavior change related to medication management and support its use in clinical trial applications.

Original languageEnglish (US)
Article number106687
JournalEpilepsy and Behavior
Volume102
DOIs
StatePublished - Jan 2020

Fingerprint

etiracetam
Partial Epilepsy
Randomized Controlled Trials
Pediatrics
Adolescent Psychiatry
Psychiatry
Clinical Trials

Keywords

  • Affective Reactivity Index
  • Antiseizure medications
  • Irritability

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Behavioral Neuroscience

Cite this

Differential antiseizure medication sensitivity of the Affective Reactivity Index : A randomized controlled trial in new-onset pediatric focal epilepsy. / Loring, David W.; Meador, Kimford J.; Shinnar, Shlomo; Gaillard, William Davis; Wheless, James W.; Kessler, Sudha K.; Conry, Joan A.; Berl, Madison M.; Burns, Thomas G.; Glauser, Tracy A.; Kinkead, Becky; Cnaan, Avital.

In: Epilepsy and Behavior, Vol. 102, 106687, 01.2020.

Research output: Contribution to journalArticle

Loring, DW, Meador, KJ, Shinnar, S, Gaillard, WD, Wheless, JW, Kessler, SK, Conry, JA, Berl, MM, Burns, TG, Glauser, TA, Kinkead, B & Cnaan, A 2020, 'Differential antiseizure medication sensitivity of the Affective Reactivity Index: A randomized controlled trial in new-onset pediatric focal epilepsy', Epilepsy and Behavior, vol. 102, 106687. https://doi.org/10.1016/j.yebeh.2019.106687
Loring, David W. ; Meador, Kimford J. ; Shinnar, Shlomo ; Gaillard, William Davis ; Wheless, James W. ; Kessler, Sudha K. ; Conry, Joan A. ; Berl, Madison M. ; Burns, Thomas G. ; Glauser, Tracy A. ; Kinkead, Becky ; Cnaan, Avital. / Differential antiseizure medication sensitivity of the Affective Reactivity Index : A randomized controlled trial in new-onset pediatric focal epilepsy. In: Epilepsy and Behavior. 2020 ; Vol. 102.
@article{34cc23a7fa8e4bfb949d9ee0b9293fe7,
title = "Differential antiseizure medication sensitivity of the Affective Reactivity Index: A randomized controlled trial in new-onset pediatric focal epilepsy",
abstract = "Background: Irritability is a adverse effect of many antiseizure medications (ASMs), but there are no validated measures currently available to characterize this behavioral risk. We examined both child and parent/guardian versions of the Affective Reactivity Index (ARI), a validated measure developed for application in adolescent psychiatry, to determine its sensitivity to ASM-related irritability. We hypothesized irritability increases associated with levetiracetam (LEV) but not lamotrigine (LTG) or oxcarbazepine (OXC). Method: The ARI was administered to 71 child and parent/guardian pairs randomized to one of three common ASMs (LEV, LTG, OXC) used to treat new-onset focal (localization-related) epilepsy. Subjects were recruited as part of a prospective multicenter, randomized, open-label, parallel group design. The ARI was administered at baseline prior to treatment initiation and again at 3 months after ASM initiation. Results: There was a significant increase in ARI ratings for both child and parent/guardian ratings for LEV but not LTG or OXC when assessed 3 months after treatment initiation. When examined on the individual subject level using a criterion of at least a 3-point ARI increase, there was an increase associated with LEV for child ratings but not parent/guardian scores. Conclusion: Both child and parent/guardian versions of the ARI appear sensitive to medication-induced irritability associated with LEV on both the group and individual levels. The findings extend the applicability of ARI from characterizing the presence of clinical irritability as a psychiatric diagnostic feature to a more modifiable aspect of behavior change related to medication management and support its use in clinical trial applications.",
keywords = "Affective Reactivity Index, Antiseizure medications, Irritability",
author = "Loring, {David W.} and Meador, {Kimford J.} and Shlomo Shinnar and Gaillard, {William Davis} and Wheless, {James W.} and Kessler, {Sudha K.} and Conry, {Joan A.} and Berl, {Madison M.} and Burns, {Thomas G.} and Glauser, {Tracy A.} and Becky Kinkead and Avital Cnaan",
year = "2020",
month = "1",
doi = "10.1016/j.yebeh.2019.106687",
language = "English (US)",
volume = "102",
journal = "Epilepsy and Behavior",
issn = "1525-5050",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Differential antiseizure medication sensitivity of the Affective Reactivity Index

T2 - A randomized controlled trial in new-onset pediatric focal epilepsy

AU - Loring, David W.

AU - Meador, Kimford J.

AU - Shinnar, Shlomo

AU - Gaillard, William Davis

AU - Wheless, James W.

AU - Kessler, Sudha K.

AU - Conry, Joan A.

AU - Berl, Madison M.

AU - Burns, Thomas G.

AU - Glauser, Tracy A.

AU - Kinkead, Becky

AU - Cnaan, Avital

PY - 2020/1

Y1 - 2020/1

N2 - Background: Irritability is a adverse effect of many antiseizure medications (ASMs), but there are no validated measures currently available to characterize this behavioral risk. We examined both child and parent/guardian versions of the Affective Reactivity Index (ARI), a validated measure developed for application in adolescent psychiatry, to determine its sensitivity to ASM-related irritability. We hypothesized irritability increases associated with levetiracetam (LEV) but not lamotrigine (LTG) or oxcarbazepine (OXC). Method: The ARI was administered to 71 child and parent/guardian pairs randomized to one of three common ASMs (LEV, LTG, OXC) used to treat new-onset focal (localization-related) epilepsy. Subjects were recruited as part of a prospective multicenter, randomized, open-label, parallel group design. The ARI was administered at baseline prior to treatment initiation and again at 3 months after ASM initiation. Results: There was a significant increase in ARI ratings for both child and parent/guardian ratings for LEV but not LTG or OXC when assessed 3 months after treatment initiation. When examined on the individual subject level using a criterion of at least a 3-point ARI increase, there was an increase associated with LEV for child ratings but not parent/guardian scores. Conclusion: Both child and parent/guardian versions of the ARI appear sensitive to medication-induced irritability associated with LEV on both the group and individual levels. The findings extend the applicability of ARI from characterizing the presence of clinical irritability as a psychiatric diagnostic feature to a more modifiable aspect of behavior change related to medication management and support its use in clinical trial applications.

AB - Background: Irritability is a adverse effect of many antiseizure medications (ASMs), but there are no validated measures currently available to characterize this behavioral risk. We examined both child and parent/guardian versions of the Affective Reactivity Index (ARI), a validated measure developed for application in adolescent psychiatry, to determine its sensitivity to ASM-related irritability. We hypothesized irritability increases associated with levetiracetam (LEV) but not lamotrigine (LTG) or oxcarbazepine (OXC). Method: The ARI was administered to 71 child and parent/guardian pairs randomized to one of three common ASMs (LEV, LTG, OXC) used to treat new-onset focal (localization-related) epilepsy. Subjects were recruited as part of a prospective multicenter, randomized, open-label, parallel group design. The ARI was administered at baseline prior to treatment initiation and again at 3 months after ASM initiation. Results: There was a significant increase in ARI ratings for both child and parent/guardian ratings for LEV but not LTG or OXC when assessed 3 months after treatment initiation. When examined on the individual subject level using a criterion of at least a 3-point ARI increase, there was an increase associated with LEV for child ratings but not parent/guardian scores. Conclusion: Both child and parent/guardian versions of the ARI appear sensitive to medication-induced irritability associated with LEV on both the group and individual levels. The findings extend the applicability of ARI from characterizing the presence of clinical irritability as a psychiatric diagnostic feature to a more modifiable aspect of behavior change related to medication management and support its use in clinical trial applications.

KW - Affective Reactivity Index

KW - Antiseizure medications

KW - Irritability

UR - http://www.scopus.com/inward/record.url?scp=85076047702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076047702&partnerID=8YFLogxK

U2 - 10.1016/j.yebeh.2019.106687

DO - 10.1016/j.yebeh.2019.106687

M3 - Article

C2 - 31816478

AN - SCOPUS:85076047702

VL - 102

JO - Epilepsy and Behavior

JF - Epilepsy and Behavior

SN - 1525-5050

M1 - 106687

ER -